Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Official Title

A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)


A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line. There will be a dose escalation part and a dose expansion part.

Trial Description

Primary Outcome:

  • Number of participants with Adverse Events (AEs) as a measure of safety and tolerability
Secondary Outcome:
  • Pharmacokinetics (PK): Ctrough
  • Pharmacokinetics (PK): Cmax
  • Pharmacokinetics (PK): AUC
  • Overall response rate (ORR) using RECIST v1.1 criteria)
  • Progression free survival (PFS)
  • Time to Progression (TTP)
  • Duration of response (DOR)
  • Time to response (TTR)
  • Disease control rate (DCR) per RECIST v1.1
  • Overall survival (OS)
  • Antidrug antibodies (ADA) prevalence at baseline and on treatment

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society